Outlook Therapeutics Inc
F:41ON
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
O
|
Outlook Therapeutics Inc
F:41ON
|
US |
|
A
|
ADTRAN Holdings Inc
XMUN:QH9
|
US |
Outlook Therapeutics Inc
Outlook Therapeutics is a biopharmaceutical company focused on eye diseases, especially retinal conditions that can threaten vision. Its main work is to develop and seek approval for an ophthalmic version of bevacizumab, a drug designed to be used in the eye rather than in its original cancer-treatment form. The company does not sell a broad range of medicines. Its business is centered on developing, testing, and commercializing one main product candidate for wet age-related macular degeneration and related retinal uses. If approved, it would sell the treatment to ophthalmologists, retina specialists, hospitals, and clinics that treat patients with these chronic eye conditions. Outlook Therapeutics makes money, when it has a product on the market, by selling prescription drug product and by working through the drug approval and launch process with regulators and healthcare providers. Its role in the industry is narrow but important: it is trying to turn an established active ingredient into a purpose-built eye treatment with a delivery format aimed at retinal care.
Outlook Therapeutics is a biopharmaceutical company focused on eye diseases, especially retinal conditions that can threaten vision. Its main work is to develop and seek approval for an ophthalmic version of bevacizumab, a drug designed to be used in the eye rather than in its original cancer-treatment form.
The company does not sell a broad range of medicines. Its business is centered on developing, testing, and commercializing one main product candidate for wet age-related macular degeneration and related retinal uses. If approved, it would sell the treatment to ophthalmologists, retina specialists, hospitals, and clinics that treat patients with these chronic eye conditions.
Outlook Therapeutics makes money, when it has a product on the market, by selling prescription drug product and by working through the drug approval and launch process with regulators and healthcare providers. Its role in the industry is narrow but important: it is trying to turn an established active ingredient into a purpose-built eye treatment with a delivery format aimed at retinal care.
EU/UK Approval: Outlook Therapeutics received marketing authorization for its ophthalmic bevacizumab in both the European Union and the United Kingdom.
US Progress: Enrollment in the NORSE EIGHT clinical trial is on track, with 359 of 400 subjects enrolled and completion expected by the end of Q3.
BLA Resubmission Timing: Top line NORSE EIGHT results are expected in Q4 2024, with BLA resubmission to the FDA planned for the first quarter of 2025.
Financial Position: Cash of $32 million as of June 30, 2024, plus potential $107 million from warrant exercises, should support operations through 2025.
R&D and G&A Expenses: R&D expenses decreased quarter-over-quarter after most NORSE EIGHT initiation costs, while G&A rose due to European prelaunch activities.
Inventory Ready: Product inventory built for prior FDA approval now being used for European launch, with shelf life being extended.
Market Access Efforts: Active work ongoing with health technology assessment agencies and payers in Europe, including NICE in the UK.
